Last reviewed · How we verify
Respiratory Syncytial Virus Prefusion F Subunit Vaccine (respiratory-syncytial-virus-prefusion-f-subunit-vaccine)
Respiratory Syncytial Virus Prefusion F Subunit Vaccine (generic name: respiratory-syncytial-virus-prefusion-f-subunit-vaccine) is a Vaccine Vaccine drug developed by Pfizer. It is currently FDA-approved for Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV disease due to prematurity., Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV disease due to certain chronic lung conditions., Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV disease due to certain heart conditions..
At a glance
| Generic name | respiratory-syncytial-virus-prefusion-f-subunit-vaccine |
|---|---|
| Sponsor | Pfizer |
| Drug class | Vaccine |
| Target | Respiratory Syncytial Virus (RSV) |
| Modality | Vaccine |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Approved indications
- Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV disease due to prematurity.
- Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV disease due to certain chronic lung conditions.
- Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV disease due to certain heart conditions.
Common side effects
Drug interactions
- Live, attenuated influenza vaccines
- Live vaccines
- Live, attenuated vaccines
- Live vaccines
- Live, attenuated influenza vaccines
- Live, attenuated vaccines
- Live vaccines
- Live, attenuated vaccines
- Live, attenuated influenza vaccines
- Live, attenuated vaccines
- Live vaccines
- Live, attenuated influenza vaccines
Key clinical trials
- A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Older Adults in Korea (PHASE3)
- Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. (PHASE3)
- A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults (PHASE3)
- A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults (PHASE1)
- A Study to Assess Safety, Tolerability and Immunogenicity of RSVpreF From Multidose Vials in Healthy Female Adults. (PHASE3)
- A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease (PHASE3)
- A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants (PHASE3)
- First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Respiratory Syncytial Virus Prefusion F Subunit Vaccine CI brief — competitive landscape report
- Respiratory Syncytial Virus Prefusion F Subunit Vaccine updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Respiratory Syncytial Virus Prefusion F Subunit Vaccine
What is Respiratory Syncytial Virus Prefusion F Subunit Vaccine?
Respiratory Syncytial Virus Prefusion F Subunit Vaccine (respiratory-syncytial-virus-prefusion-f-subunit-vaccine) is a Vaccine drug developed by Pfizer, indicated for Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV disease due to prematurity., Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV disease due to certain chronic lung conditions., Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV disease due to certain heart conditions..
What is Respiratory Syncytial Virus Prefusion F Subunit Vaccine used for?
Respiratory Syncytial Virus Prefusion F Subunit Vaccine is indicated for Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV disease due to prematurity., Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV disease due to certain chronic lung conditions., Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV disease due to certain heart conditions..
Who makes Respiratory Syncytial Virus Prefusion F Subunit Vaccine?
Respiratory Syncytial Virus Prefusion F Subunit Vaccine is developed and marketed by Pfizer (see full Pfizer pipeline at /company/pfizer).
What is the generic name of Respiratory Syncytial Virus Prefusion F Subunit Vaccine?
respiratory-syncytial-virus-prefusion-f-subunit-vaccine is the generic (nonproprietary) name of Respiratory Syncytial Virus Prefusion F Subunit Vaccine.
What drug class is Respiratory Syncytial Virus Prefusion F Subunit Vaccine in?
Respiratory Syncytial Virus Prefusion F Subunit Vaccine belongs to the Vaccine class. See all Vaccine drugs at /class/vaccine.
What development phase is Respiratory Syncytial Virus Prefusion F Subunit Vaccine in?
Respiratory Syncytial Virus Prefusion F Subunit Vaccine is FDA-approved (marketed).
What does Respiratory Syncytial Virus Prefusion F Subunit Vaccine target?
Respiratory Syncytial Virus Prefusion F Subunit Vaccine targets Respiratory Syncytial Virus (RSV) and is a Vaccine.
Related
- Drug class: All Vaccine drugs
- Target: All drugs targeting Respiratory Syncytial Virus (RSV)
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV disease due to prematurity.
- Indication: Drugs for Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV disease due to certain chronic lung conditions.
- Indication: Drugs for Prevention of severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants with a high risk of RSV disease due to certain heart conditions.
- Compare: Respiratory Syncytial Virus Prefusion F Subunit Vaccine vs similar drugs
- Pricing: Respiratory Syncytial Virus Prefusion F Subunit Vaccine cost, discount & access